Compare VTSI & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTSI | RNTX |
|---|---|---|
| Founded | 1993 | 2001 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 57.8M |
| IPO Year | 1999 | 2017 |
| Metric | VTSI | RNTX |
|---|---|---|
| Price | $2.62 | $0.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $6.25 | $6.00 |
| AVG Volume (30 Days) | 26.9K | ★ 443.5K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $185,971.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $0.54 |
| 52 Week High | $6.08 | $2.18 |
| Indicator | VTSI | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 48.32 |
| Support Level | $2.54 | $0.54 |
| Resistance Level | $2.82 | $0.87 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 32.14 | 59.50 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.